- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07483450
재발성 다발성 경화증과 1차 진행성 다발성 경화증 환자에서 Ocrelizumab의 효능, 안전성, 약동학 및 약력학을 평가하는 연구
중국인 재발성 다발성 경화증 및 원발성 진행성 다발성 경화증 환자에서 Ocrelizumab의 효능, 안전성, 약동학 및 약력학을 평가하기 위한 다기관, 개방형, 단일군 연구
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
연구 개요
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Beijing, 중국, 100034
- Peking University First Hospital
-
Beijing, 중국, 100032
- Peking Union Medical College Hospital
-
Beijing, 중국, 100730
- Beijing Hospital of Ministry of Health
-
Changsha, 중국, 410008
- Xiangya Hospital Central South University
-
Chengdu, 중국, 610041
- West China Hospital of Sichuan University
-
Chongqing, 중국, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, 중국, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, 중국, 510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou, 중국, 310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot, 중국, 010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou, 중국, 730030
- Lanzhou University Second Hospital
-
Shenyang, 중국, DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang, 중국, 050000
- The Second Hospital of Hebei Medical University
-
Taiyuan, 중국, 030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan, 중국, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi, 중국, 830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330209
- The First Affiliated Hospital of Nanchang University
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
다른 이름들:
|
|
실험적: PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
RMS 코호트: 연간 프로토콜 정의 재발률
기간: 약 1.6년까지
|
약 1.6년까지
|
|
PPMS 코호트: 혈액 내 B세포 수준
기간: 최대 48주까지
|
최대 48주까지
|
|
PPMS 코호트: 48주차에 클러스터 분화 항원 19(CD19+) B세포 수준이 <10세포/마이크로리터(μL)에 도달한 참가자 비율
기간: 48주차에
|
48주차에
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
RMS 코호트: 48주 기간 동안 질병 활동성 증거가 없는(NEDA3) 참가자 비율
기간: 최대 48주까지
|
최대 48주까지
|
|
|
RMS 코호트: 48주차까지 재발 없는 참가자 비율
기간: 최대 48주
|
최대 48주
|
|
|
RMS 코호트: 24주 기간 동안 NEDA3를 달성한 참가자의 비율
기간: 최대 24주까지
|
최대 24주까지
|
|
|
RMS 코호트: 뇌 자기공명영상(MRI)으로 검출된 총 T1 가돌리늄(Gd) 조영 병변 수
기간: 최대 48주
|
최대 48주
|
|
|
RMS 코호트: 뇌 MRI로 감지된 새로운 또는 확대된 T2 고신호 병변의 총 수
기간: 최대 48주까지
|
최대 48주까지
|
|
|
RMS 및 PPMS 코호트: 기준선부터 48주까지의 혈청 신경섬유 경쇄(Nfl) 농도 변화
기간: 기저선부터 48주까지
|
기저선부터 48주까지
|
|
|
RMS 및 PPMS 코호트: 오크렐리주맙의 혈청 농도
기간: 최대 48주까지
|
최대 48주까지
|
|
|
RMS 코호트: 혈액 내 B-세포 수준
기간: 최대 48주까지
|
최대 48주까지
|
|
|
RMS 코호트: 48주차에 CD19+ B세포 수준이 <10 cells/μL에 도달한 참가자 비율
기간: 48주차에
|
48주차에
|
|
|
PPMS 코호트: 뇌 MRI로 검출된 24주차 및 48주차 T1 조영증강 병변의 총 수
기간: 24주와 48주
|
24주와 48주
|
|
|
PPMS 코호트: 주 24 및 주 48 뇌 MRI로 검출된 새로운 또는 확대된 T2 고신호 병변의 총 수
기간: 24주차 및 48주차
|
24주차 및 48주차
|
|
|
RMS 및 PPMS 코호트: 이상사례(AE)가 발생한 참가자 수
기간: 최대 약 1.8년
|
최대 약 1.8년
|
|
|
RMS 및 PPMS 코호트: 기준선 대비 T-세포 수준 변화
기간: 약 1.8년까지
|
약 1.8년까지
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
기간: Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
기간: Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
기간: Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
기간: Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
기간: Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trials, Hoffmann-La Roche
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- YN44938
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .